Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model

Masashi Kasuya, Kenichi Meguro

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The previous health economic simulation of donepezil based on the Markov model revealed the treatment for mild to moderate stage of Alzheimer disease (AD) to be cost-effective. Our aim was to examine the economic effect of donepezil treatment for mild cognitive impairment, from which about 15% convert to dementia per year. We constructed a new Markov model using three simulations. Namely, Simulation A hypothesized that mild AD patients, i.e., Clinical Dementia Rating (CDR) 1, received donepezil as in the previous study. Simulation B hypothesized that all CDR 0.5 subjects received donepezil, and Simulation C considered that only the CDR 0.5 converters to dementia received donepezil. We calculated the models as follows: Simulation B, supposes that the annual transition probabilities were reduced even from 15% to 10% by donepezil, however, the drug had a negative economic effect. By contrast, in Simulation C, the annual transition probability was reduced from only 15% to 12% by donepezil, there was a positive economic effect. Since it is necessary to reduce the annual transition probability from 15% to 12% in order to manifest a concomitant economic benefit, we consider that early detection of CDR 0.5 converters in the community is important for health policy planning.

Original languageEnglish
Pages (from-to)295-299
Number of pages5
JournalArchives of Gerontology and Geriatrics
Volume50
Issue number3
DOIs
Publication statusPublished - 2010 May

Keywords

  • Alzheimer's disease
  • Clinical Dementia Rating 0.5
  • Cost-utility analysis
  • Donepezil
  • Mild cognitive impairment
  • Quality-adjusted life years

ASJC Scopus subject areas

  • Health(social science)
  • Ageing
  • Gerontology
  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model'. Together they form a unique fingerprint.

Cite this